Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19340
Full metadata record
DC FieldValueLanguage
dc.contributor.authorContopoulos-Ioannidis, D. G.en
dc.contributor.authorKouri, I.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T18:59:05Z-
dc.date.available2015-11-24T18:59:05Z-
dc.identifier.issn1744-8042-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19340-
dc.rightsDefault Licence-
dc.subject*Adrenergic beta-2 Receptor Agonistsen
dc.subject*Adrenergic beta-Agonists/pharmacologyen
dc.subjectAnimalsen
dc.subjectHumansen
dc.subjectPharmacogenetics/*methodsen
dc.subjectPolymorphism, Genetic/drug effects/geneticsen
dc.subjectReceptors, Adrenergic, beta-2/*geneticsen
dc.titlePharmacogenetics of the response to beta 2 agonist drugs: a systematic overview of the fielden
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.2217/14622416.8.8.933-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17716228-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractThe response to beta2-agonist treatment shows large repeatability within individuals and may thus be determined by genetic influences. Here we present a systematic overview of the available genetic association and linkage data for beta2-agonist treatment response. Systematic searches identified 66 eligible articles, as of March 2007, pertaining either to B2AR gene polymorphisms and short-acting or long-acting beta2-agonists or to another 29 different genes. We systematize these study results according to gene, agent and type of outcomes addressed. The systematic review highlights major challenges in the field, including extreme multiplicity of analyses; lack of consensus for main phenotypes of interest; typically small sample sizes; and poor replicability of the proposed genetic variants. Future studies will benefit from standardization of analyses and outcomes, hypothesis-free genome-wide association testing platforms, potentially additional fine mapping around new discovered variants, and large-scale collaborative studies with prospective plans for replication among several teams, with transparent public recording of all data.en
heal.journalNamePharmacogenomicsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons